Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1
Phytotherapy Research · 2023
DOI: 10.1002/ptr.7942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2023. Verfasst von Zheng Zeng und 22 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Research Center, Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicin…. Hauptthemen laut MEDLINE: Thrombospondin 1, Ovarian Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: China Scholarship Council, College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding, Heilongjiang Postdoctoral Financial Assistance.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) is the most common and fatal subtype of ovarian malignancies, with no effective therapeutics available. Our previous studies have demonstrated extraordinary suppressive efficacy of enterolactone (ENL) on EOC. A chemotherapeutic agent, trabectedin (Trabe), is shown to be effective on ovarian cancer, especially when combined with other therapeutics, such as pegylated liposomal doxorubicin or oxaliplatin. Thrombospondin 1 (THBS1), a kind of matrix glycoprotein, plays important roles against cancer development through inhibiting angiogenesis but whether it is involved in the suppression of EOC by ENL or Trabe remains unknown. To test combined suppressive effects of ENL and Trabe on EOC and possible involvement of THBS1 in the anticancer activities of ENL and Trabe. The EOC cell line ES‐2 was transfected with overexpressed THBS1 by lentivirus vector. We employed tube formation assay to evaluate the anti‐angiogenesis activity of ENL and of its combined use with Trabe after THBS1 overexpression and established drug intervention and xenograft nude mouse cancer models to assess the in vivo effects of the hypothesized synergistic suppression between the agents and the involvement of THBS1. Mouse fecal samples were collected for 16S rDNA sequencing and microbiota analysis. We detected strong inhibitory activities of ENL and Trabe against the proliferation and migration of cancer cells and observed synergistic effects between ENL and Trabe in suppressing EOC. ENL and Trabe, given either separately or in combination, could suppress the tube formation capability of human microvascular endothelial cells, and this inhibitory effect became even stronger with THBS1 overexpression. In the ENL plus Trabe combination group, the expression of tissue inhibitor of metalloproteinases 3 and cluster of differentiation 36 was both upregulated, whereas matrix metalloproteinase 9, vascular endothelial growth factor, and cluster of differentiation 47 were all decreased. With the overexpression of THBS1, the results became even more pronounced. In animal experiments, combined use of ENL and Trabe showed superior inhibitory effects to either single agent and significantly suppressed tumor growth, and the overexpression of THBS1 further enhanced the anti‐cancer activities of the drug combination group. ENL and Trabe synergistically suppress EOC and THBS1 could remarkably facilitate the synergistic anticancer effects of ENL and Trabe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics Research Center, Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical Universi…
- Harbin Medical University-University of Calgary Cumming School of Medicine Centre for Infection and Genomics, Harbin Medical University, Harbin, China.
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada.
- School of Biomedical Science, The University of Hong Kong, Hong Kong.
- School of Basic Medicine, Harbin Medical University, Harbin, China.
- Department of Pathology, Harbin Chest Hospital, Harbin, China.
ORCID-Profile: Shu-Lin Liu, Huidi Liu
Förderung
- China Scholarship Council
- College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding
- Heilongjiang Postdoctoral Financial Assistance
- HMU Marshal Initiative Funding
- Merit-based Funding for Returned Oversea Students in Heilongjiang Province
- National Natural Science Foundation of China
Zitieren
APA
Zeng, Z., Lin, C., Zhang, M. C., Kossinna, P., Wang, P., Cao, D., Wang, J., Xu, M., Wang, X., Li, Q., Xu, X., Yang, H., Zhu, S., Liu, G. R., Xie, K., Yang, J., Luo, Y., Wang, Y., Zhang, X. H., …, & Liu, H. (2023). Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1. Phytotherapy Research. https://doi.org/10.1002/ptr.7942
Vancouver
Zeng Z, Lin C, Zhang MC, Kossinna P, Wang P, Cao D, et al. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1. Phytotherapy Research. 2023. doi:10.1002/ptr.7942
BibTeX
@article{Zeng2023,
author = {Zeng, Zheng and Lin, Caiji and Zhang, Meng-Chun and Kossinna, Pathum and Wang, Pengfei and Cao, Danli and Wang, Jiaxing and Xu, Mengzhi and Wang, Xiaoyu and Li, Qing and Xu, Xiaohui and Yang, Hao and Zhu, Songling and Liu, Gui-Rong and Xie, Kaihong and Yang, Jiaming and Luo, Yao and Wang, Yao and Zhang, Xing-Hua and Lin, Jingwen and Chen, Hang and Liu, Shu-Lin and Liu, Huidi},
title = {Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1},
journal = {Phytotherapy Research},
year = {2023},
doi = {10.1002/ptr.7942}
}
EUVIMED